학술논문
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
Document Type
Academic Journal
Author
Lucà, Fabiana; Oliva, Fabrizio; Abrignani, Maurizio Giuseppe; Di Fusco, Stefania Angela; Gori, Mauro; Giubilato, Simona; Ceravolo, Roberto; Temporelli, Pier Luigi; Cornara, Stefano; Rao, Carmelo Massimiliano; Caretta, Giorgio; Pozzi, Andrea; Binaghi, Giulio; Maloberti, Alessandro; Di Nora, Concetta; Di Matteo, Irene; Pilleri, Anna; Gelsomino, Sandro; Riccio, Carmine; Grimaldi, Massimo; Colivicchi, Furio; Gulizia, Michele Massimo
Source
Journal of Clinical Medicine. February 2024, Vol. 13 Issue 5
Subject
Language
English
ISSN
2077-0383
Abstract
Author(s): Fabiana Lucà (corresponding author) [1,*]; Fabrizio Oliva [2]; Maurizio Giuseppe Abrignani [3]; Stefania Angela Di Fusco [4]; Mauro Gori [5]; Simona Giubilato [6]; Roberto Ceravolo [7]; Pier Luigi Temporelli [...]
Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.
Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.